Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8410077 | ACROTECH | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
US9200088 | ACROTECH | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
US11020363 | ACROTECH | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
May, 2030
(7 years from now) | |
US10864183 | ACROTECH | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
May, 2030
(7 years from now) | |
US10940128 | ACROTECH | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
Jun, 2030
(7 years from now) | |
US9493582 | ACROTECH | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) | |
US10040872 | ACROTECH | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Jan, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Mar 10, 2023 |
Market Authorisation Date: 10 March, 2016
Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma
Dosage: POWDER;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic